Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Aug;43(2):274-278.
doi: 10.1016/j.bone.2008.03.027. Epub 2008 Apr 15.

Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women

G J van Londen  1 , S Perera  2 , K T Vujevich  3 , S M Sereika  4 , R Bhattacharya  5 , S L Greenspan  3
Affiliations
Randomized Controlled Trial

Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women

G J van Londen et al. Bone. 2008 Aug.

Abstract

Introduction: Chemotherapy-induced menopause is associated with bone loss. The effect on structural geometry is unknown. Our objective was to determine if oral bisphosphonate therapy could maintain or improve femoral geometry in breast cancer patients with chemotherapy-induced menopause.

Methods: This preplanned 1 year interim, secondary analysis of the Risedronate's Effect on Bone loss in Breast CAncer Study (REBBeCA Study) examined hip structure analysis (HSA), i.e. changes in the bone cross-sectional area (bone CSA), section modulus (SM: measure of bending strength), cortical thickness (CT) and buckling ratio (BR: index of cortical bone stability), in a double-blind trial of 87 newly postmenopausal, nonmetastatic breast cancer patients, randomized to risedronate, 35 mg once weekly (RIS) versus placebo (PBO).

Results: After 12 months, intertrochanteric parameters demonstrated percentage improvement (RIS vs. PBO) from baseline in bone CSA (mean+/-SD: 4.25+/-6.29 vs. 0.60+/-5.99%), SM (3.97+/-6.40 vs. 0.80+/-7.08%), and CT [5.20+/-6.98 vs. 1.13+/-6.87% (all p-values <0.05 except SM p=0,0643)]. Similar improvements were observed at the femoral shaft [bone CSA: 2.24+/-5.74 vs. -0.78+/-5.73%; SM: 1.62+/-6.23 vs. -1.39+/-7.06%; CT: 3.79+/-7.84 vs. -0.17+/-7.90% (all p-values <0.05, RIS vs. PBO, except SM p= p =0.0568)]. At both sites, the BR had significant decreases consistent with improved strength.

Conclusion: We conclude that RIS improves measures of hip structural geometry in women with breast cancer following chemotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:

  1. Dr Bhattacharya has received an investigator initiated grant from ‘Procter & Gamble’.

  2. Dr Greenspan has received grant-support from ‘Procter & Gamble’, Merck Research Laboratories, Amgen, Zelos and Novartis. Dr Greenspan also serves as a consultant for ‘Procter & Gamble’, Merck Research Laboratories, Amgen, Zelos and NPS Allelix.

  3. Dr Perera has received funding from Eli Lilly & Co for an observational research project.

  4. All other authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Percent change in the (A) intertrochanteric region, (B) femoral shaft, and (C) narrow neck cross-sectional parameters measured by HSA after one year of therapy with risedronate versus placebo of newly postmenopausal women due to adjuvant chemotherapy for breast cancer. Results are mean ± SE (formula image p-value < 0.05 risedronate vs. placebo, formula image p-value < 0.05 difference from baseline). Abbreviations: Bone CSA – Bone Cross Sectional Area, SM – Section Modulus, CT – Cortical Thickness, OD – Outer Diameter, BR – Buckling Ratio.
Figure 1
Figure 1
Percent change in the (A) intertrochanteric region, (B) femoral shaft, and (C) narrow neck cross-sectional parameters measured by HSA after one year of therapy with risedronate versus placebo of newly postmenopausal women due to adjuvant chemotherapy for breast cancer. Results are mean ± SE (formula image p-value < 0.05 risedronate vs. placebo, formula image p-value < 0.05 difference from baseline). Abbreviations: Bone CSA – Bone Cross Sectional Area, SM – Section Modulus, CT – Cortical Thickness, OD – Outer Diameter, BR – Buckling Ratio.
Figure 1
Figure 1
Percent change in the (A) intertrochanteric region, (B) femoral shaft, and (C) narrow neck cross-sectional parameters measured by HSA after one year of therapy with risedronate versus placebo of newly postmenopausal women due to adjuvant chemotherapy for breast cancer. Results are mean ± SE (formula image p-value < 0.05 risedronate vs. placebo, formula image p-value < 0.05 difference from baseline). Abbreviations: Bone CSA – Bone Cross Sectional Area, SM – Section Modulus, CT – Cortical Thickness, OD – Outer Diameter, BR – Buckling Ratio.
See this image and copyright information in PMC

References

    1. American Cancer Society. Breast Cancer Facts and Figures, 2005–2006. [Accessed December 28, 2006]. Available at http://www.cancer.org/downloads/STT/CAFF2005BrF.pdf.
    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130. - PubMed
    1. Group, E. B. C. T. C. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. [see comment] - PubMed
    1. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology. 1996;14:1718–1729. [see comment] - PubMed
    1. Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Research & Treatment. 1997;43:183–190. - PubMed

Publication types

MeSH terms